Pre-made Epratuzumab benchmark antibody ( Whole mAb, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-190-1mg	1mg	3090
GMP-Bios-ab-190-10mg	10mg	Inquiry
GMP-Bios-ab-190-100mg	100mg	Inquiry
GMP-Bios-ab-190-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
INN Name	Epratuzumab
Target	CD22
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	5vkk:AB:HL/5vl3:EF:AB:HL:CD
95-98% SI Structure	None
Year Proposed	1999
Year Recommended	2000
Companies	Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia
Development Tech	na